Protective Effects of Pasireotide in LPS-Induced Acute Lung Injury

Area of Science:

• Pulmonary Medicine
• Inflammation Research
• Pharmacology

Background:

• Acute lung injury (ALI) involves inflammation and barrier damage, leading to impaired gas exchange.
• Lipopolysaccharides (LPS) from Gram-negative bacteria activate Toll-like receptor 4 (TLR4), initiating inflammatory responses.
• Understanding ALI pathogenesis is crucial for developing effective treatments.

Purpose of the Study:

• To investigate the potential protective effects of Pasireotide (PAS) in an experimental model of ALI.
• To determine if PAS can mitigate LPS-induced lung inflammation and injury.
• To explore the molecular mechanisms underlying PAS's effects on lung barrier integrity.

Main Methods:

• An experimental model of ALI was established in C57BL/6 male mice using intratracheal LPS instillation.
• Mice were treated with either PAS or a vehicle control.
• Bronchoalveolar lavage fluid (BALF) and lung tissue were analyzed using Western blot to assess protein expression and inflammatory markers.

Main Results:

• PAS treatment significantly alleviated LPS-induced lung injury and inflammation in mice.
• PAS suppressed the activation of JAK/STAT and MAPK signaling pathways in inflamed lungs.
• PAS treatment counteracted LPS-induced reduction in Grp94 protein, indicating involvement of the ATF6 pathway in barrier protection.

Conclusions:

• Pasireotide (PAS) demonstrates significant protective effects against lipopolysaccharide (LPS)-induced acute lung injury (ALI) in a mouse model.
• PAS mitigates lung inflammation and barrier dysfunction by inhibiting key inflammatory signaling pathways.
• The findings suggest that PAS may be a potential therapeutic agent for ALI.